Arch Venture Management LLC: Significant Investment Increase in BOLD During Q2 2026

Arch Venture Management, Llc held a substantial portfolio value of $586.8 million as of June 30th, 2026, maintaining an almost exclusive allocation within the Healthcare sector at 100%.

The investment firm demonstrated notable activity during this quarter, with two stocks showing changes in their holdings compared to the previous period:

• Boundless Bio Inc (BOLD) experienced a significant increase of 100% in its shareholding from Q1 2026.
• Vir Biotechnology Inc (VIR) saw a slight decrease of approximately 1.72% in shares held during this quarter.

The largest change was observed in Boundless Bio Inc (BOLD). The investor acquired an additional 2,694,095 shares, bringing the total holdings to that number and representing a substantial new investment into the company. This significant increase suggests strong confidence or alignment with BOLD's strategic direction during this period.

In contrast, Vir Biotechnology Inc (VIR) experienced a modest reduction in its position. The investor sold 222,500 shares of VIR, resulting in a decrease of about 1.72% in the portfolio allocation for this stock.

The other significant holdings remained unchanged during Q2 2026: Beam Therapeutics Inc (BEAM), Rapport Therapeutics Inc (RAPP), and EraScalla Inc (ERAS) all maintained their share counts and values, contributing significantly to the overall portfolio weight. The Healthcare sector allocation stayed intact at its entirety.

Overall, Arch Venture Management's portfolio held 7 distinct positions this quarter, with the top five holdings accounting for approximately 52.6% of the total value. The investor showed a clear preference for increasing exposure to emerging opportunities within Healthcare, as evidenced by the substantial stake increase in BOLD.